The secretary of health and environment shall implement a drug utilization review program with the assistance of a medicaid drug utilization review board as provided in K.S.A. 39-7,119, and amendments thereto, to assure the appropriate utilization of drugs by patients receiving medical assistance under the medicaid program. The drug utilization review program shall include:
(a) Monitoring of prescription information including overutilization and underutilization of prescription-only drugs;(b) making periodic reports of findings and recommendations to the secretary of health and environment and the United States department of health and human services regarding the activities of the board, drug utilization review programs, summary of interventions, assessments of education interventions and drug utilization review cost estimates;(c) providing for prospective and retrospective drug utilization review, as specified in the federal omnibus budget reconciliation act of 1990 (public law 101-508);(d) monitoring provider and recipient compliance with program objectives;(e) providing educational information on state program objectives, directly or by contract, to private and public sector health care providers to improve prescribing and dispensing practices;(f) reviewing the increasing costs of purchasing prescription drugs and making recommendations on cost containment;(g) reviewing profiles of medicaid beneficiaries who have multiple prescriptions above a level specified by the board; and(h) recommending any modifications or changes to the medicaid prescription drug program.Amended by L. 2012, ch. 102,§ 7, eff. 7/1/2012.L. 1990, ch. 214, § 3; L. 1994, ch. 254, § 1; L. 2002, ch. 180, § 6; L. 2005, ch. 187, § 23; L. 2005, ch. 187, § 52; July 1, 2006.